More affordable healthcare
Demand for biological medicines appears at a time when healthcare systems are under pressure to generate savings and efficiencies. But due to the complex way biological medicines are developed and produced, they count among the most expensive medicines available on the market. The idea behind biosimilars is to give more people access to affordable healthcare.
Biosimilars are approximately 20 to 25% more cost-effective than the reference products.*
*Pro Generika e.V.
Why choose biosimilars?
Biosimilars offer a range of potential benefits for providers, patients and payers.
More affordable than the reference biologics, which clinicians can be reluctant to prescribe.
An additional therapy for patients with serious and life-threatening diseases.
The same high standards of quality, safety, and efficacy as the biological medicine's corresponding reference product.
Assessed by the European Medicines Agency (EMA), and approved by the European Commission for use in EU patients.
Potential savings and efficiencies to relieve pressure on healthcare systems.
The health of people is our priority at STADA. Through an easier access to safe and affordable treatments, the well-being of the patients can be significantly improved.
Competition cuts costs
Just like generic medicines, such as own-brand aspirins, biosimilars lead to more competition, which reduces the cost of the medicines. However, the price difference will not be as significant as the difference between a generic copy of a chemically produced drug and its reference product. This is due to the fact that biosimilars are made by using highly complex biotechnological processes and take considerably more time and effort to be developed and controlled in the production process. Furthermore, a significant amount of clinical data needs to be submitted before biosimilars can gain approval from European authorities.